252 related articles for article (PubMed ID: 33620122)
1. Synthesis and Biological Evaluation of 1,3,5-Trisubstituted 2-Pyrazolines as Novel Cyclooxygenase-2 Inhibitors with Antiproliferative Activity.
Vahedpour T; Kaur J; Hemmati S; Hamzeh-Mivehroud M; Alizadeh AA; Wuest F; Dastmalchi S
Chem Biodivers; 2021 Mar; 18(3):e2000832. PubMed ID: 33620122
[TBL] [Abstract][Full Text] [Related]
2. Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition.
Ren SZ; Wang ZC; Zhu XH; Zhu D; Li Z; Shen FQ; Duan YT; Cao H; Zhao J; Zhu HL
Bioorg Med Chem; 2018 Aug; 26(14):4264-4275. PubMed ID: 30031652
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.
Grover J; Kumar V; Sobhia ME; Jachak SM
Bioorg Med Chem Lett; 2014 Oct; 24(19):4638-4642. PubMed ID: 25219899
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
Chen Z; Wang ZC; Yan XQ; Wang PF; Lu XY; Chen LW; Zhu HL; Zhang HW
Bioorg Med Chem Lett; 2015 May; 25(9):1947-51. PubMed ID: 25866240
[TBL] [Abstract][Full Text] [Related]
6. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antitumor activity, and molecular docking study of 2-cyclopentyloxyanisole derivatives: mechanistic study of enzyme inhibition.
El-Husseiny WM; El-Sayed MA; El-Azab AS; AlSaif NA; Alanazi MM; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):744-758. PubMed ID: 32183576
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation, and docking studies of some novel chalcones as selective COX-2 inhibitors.
Kaya Çavuşoğlu B; Sağlık BN; Acar Çevik U; Osmaniye D; Levent S; Özkay Y; Kaplancıklı ZA
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000273. PubMed ID: 33244799
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine-2,5-dione Hybrids as Potential Antitumor Agents.
Tilekar K; Upadhyay N; Meyer-Almes FJ; Loiodice F; Anisimova NY; Spirina TS; Sokolova DV; Smirnova GB; Choe JY; Pokrovsky VS; Lavecchia A; S Ramaa C
ChemMedChem; 2020 Oct; 15(19):1813-1825. PubMed ID: 32715626
[TBL] [Abstract][Full Text] [Related]
10. Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies.
Sever B; Altıntop MD; Kuş G; Özkurt M; Özdemir A; Kaplancıklı ZA
Eur J Med Chem; 2016 May; 113():179-86. PubMed ID: 26927686
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.
Fioravanti R; Bolasco A; Manna F; Rossi F; Orallo F; Ortuso F; Alcaro S; Cirilli R
Eur J Med Chem; 2010 Dec; 45(12):6135-8. PubMed ID: 20974503
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents.
Abdelgawad MA; Bakr RB; Omar HA
Bioorg Chem; 2017 Oct; 74():82-90. PubMed ID: 28772160
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
[TBL] [Abstract][Full Text] [Related]
15. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel aminophosphonate derivatives containing pyrazole moiety as potential selective COX-2 inhibitors.
Zhang B; Hu XT; Zhou KM; Yang YS; Zhu HL
Bioorg Chem; 2020 Sep; 102():104096. PubMed ID: 32707279
[TBL] [Abstract][Full Text] [Related]
17. New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects.
Güngör T; Ozleyen A; Yılmaz YB; Siyah P; Ay M; Durdağı S; Tumer TB
Eur J Med Chem; 2021 Oct; 221():113566. PubMed ID: 34077833
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies.
El-Azab AS; Abdel-Aziz AA; Abou-Zeid LA; El-Husseiny WM; El Morsy AM; El-Gendy MA; El-Sayed MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):989-998. PubMed ID: 29806488
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.
Reddy MV; Billa VK; Pallela VR; Mallireddigari MR; Boominathan R; Gabriel JL; Reddy EP
Bioorg Med Chem; 2008 Apr; 16(7):3907-16. PubMed ID: 18272371
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
Li Z; Wang ZC; Li X; Abbas M; Wu SY; Ren SZ; Liu QX; Liu Y; Chen PW; Duan YT; Lv PC; Zhu HL
Eur J Med Chem; 2019 May; 169():168-184. PubMed ID: 30877972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
